Latest information on COVID-19
Support teaching, research, and patient care.
Renumathy Dhanasekaran MD is an Assistant Professor in the Division of Gastroenterology and Hepatology at the School of Medicine, Stanford University. Her primary research goal is to explore the molecular biology of liver cancer in order to identify novel biomarkers and molecular-targeted therapies. She conducts basic and translational research to understand the molecular mechanisms of liver cancer metastasis and dormancy using mouse models of liver cancer. Also, she plays an active role in the cancer genome atlas (TCGA) consortium effort to translate the knowledge gained from the study of genomics of liver cancer. She maintains a bio-repository of tissue and blood samples from patients with liver cancer and has also developed several patient derived xenograft (PDX) models for preclinical testing. Dr. Dhanasekaran is a recipient of the American College of Gastroenterology (ACG) Junior Faculty Career Development award and the NIH/NCI K08 career development award.Dr. Dhanasekaran completed her medical school training in India, and pursued her Internal Medicine residency at the University of Florida, Gainesville followed by Gastroenterology fellowship at Mayo Clinic, Rochester and Transplant Hepatology fellowship at Stanford University. Dr. Dhanasekaran is board certified in Internal Medicine and Gastoenterology. Her clinical practice is mainly focused on liver cancer and she runs a clinic specifically for patients with liver masses.Lab Website https://med.stanford.edu/dhanasekaran-lab.html
The overall goal of my research is to understand the molecular pathogenesis of liver cancer and identify biologically relevant prognostic biomarkers and molecular targets for therapy in patients with hepatocellular carcinoma (HCC). My current ongoing projects focus on these areas-1. Drivers of tumor dormancy and recurrence of hepatocellular carcinoma (HCC)2. Drivers of metastatic tumor progression in HCC3. Prognostic gene signature for HCC4. Glycoproteomic biomarkers of HCC5. Using tumor cell free DNA (cfDNA) as biomarkers for HCC6. Tumor progression of HCC in non alcoholic steatohepatitis (NASH)
COVID-19 in Patients With Chronic Liver Diseases
This study seeks to determine how COVID-19 affects the clinical outcome of patients with
chronic liver disease, and whether the clinical course of COVID-19 is influenced by
underlying chronic liver disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details